Urine Albendazole Levels for Coverage Assessment

• Status: Completed
• Trial end date: 2020-02-28
• Target enrollment: 0
• Participant gender: All

Summary

This project will develop and assess the feasibility and acceptability of a urine-based assay to monitor adherence to Mass Drug Administration (MDA) campaigns within Soil-transmitted helminthiasis (STH) control programs, evaluating the urine and serum pharmacokinetics of ALBENDAZOLE (ABZ) and its metabolites across a variety of food/fast conditions, age, gender and body weight. The final goal is to obtain a field ready tool for the measurement of adherence to anthelmintic treatment at a community level that serves as a coverage/adherence indicator and a reference standard for other monitoring tools.

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Universidad Nacional de Salta
• Collaborators: CIVETAN-Tandil, UNCPBA; Fundacion Mundo Sano; Natural History Museum, London, UK
• Treatments: Albendazole

Criteria

Inclusion Criteria:

• Body Mass Index: 18 to 25.

• Physical exam without significant abnormal findings

Exclusion Criteria:

• Pregnancy

• Lactation

• Use of ABZ or other benzimidazole drugs in the previous 30 days.

• History of intolerance to ABZ.

• Malabsorption and/or other gastrointestinal conditions that might compromise ABZ absorption.